Insulet Corporation
Jun 9, 2017
PDF

Insulet to Preview New Clinical Data and Next Generation Omnipod® System at the American Diabetes Association's 77th Scientific Sessions

Company Further Demonstrates Significant Impact on Improving the Quality of Life of People with Diabetes

BILLERICA, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it will present new data for its Omnipod System including results from a hybrid closed-loop study utilizing the Omnipod Horizon™ Automated Glucose Control System (Omnipod Horizon System) involving a total of 24 pediatric patients from six to 18 years of age at the American Diabetes Association (ADA) 77th Scientific Sessions at the San Diego Convention Center June 9-13, 2017.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170609005121/en/

"We are deeply committed to delivering product innovation that provides our Podders with the technology and support they need to simplify their lives and ease the burden of diabetes," said Shacey Petrovic, President and Chief Operating Officer. "With this compelling clinical data and groundbreaking new technology in development, we continue to provide our users and their health care providers with robust and simplified solutions to enhance quality of life and promote successful diabetes management."

Insulet will exhibit at this year's Scientific Session at Booth Location 507 and have four poster presentations to share new clinical data supporting the benefits of both its current Omnipod System, as well as its Omnipod Horizon Automated Glucose Control System.

Dr. Bruce Buckingham, Professor of Pediatric Endocrinology at the Lucille Salter Packard Children's Hospital, Stanford University, and Principal Investigator, will be presenting the hybrid closed-loop study outcomes.

 

Omnipod presentations at ADA include:

                 
Poster Number & Title*      

Date / PT

      Location

1744-P: Impact of the Omnipod Insulin Management System
on Glycemic Control: A Survey of the T1D Exchange Glu
Online Community

      Saturday, June 10, 11:30 a.m. - 12:30 p.m.       Poster Hall

132-LB: Safety and Feasibility of Omnipod Hybrid Closed-
Loop in Children Aged 6-12 Years with Type 1 Diabetes
Using a Personalized Model Predictive Control Algorithm

      Sunday, June 11, 12:00 p.m. - 1:00 p.m.       Poster Hall

1055-P: Safety and Feasibility of Omnipod Hybrid Closed
-Loop in Adolescents with Type 1 Diabetes Using a
Personalized Model Predictive Control Algorithm

      Sunday, June 11, 12:00 p.m. - 1:00 p.m.       Poster Hall

1423-P: A Quality Improvement Protocol Using Only
Tubeless Insulin Pumps for Treatment of Hospitalized
Children and Adolescents with Diabetes Mellitus

      Monday, June 12, 12:00 p.m. - 1:00 p.m.       Poster Hall

* Data subject to embargo until Saturday, June 10, 2017

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is a revolutionary and easy-to-use tubeless insulin pump that provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to adapt the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 28, 2017 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

© 2017 Insulet Corporation, Horizon, Omnipod and Podder are trademarks or registered trademarks of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation.

Insulet Corporation
Deborah R. Gordon, 978-600-7717
Vice President, Investor Relations and Corporate Communications
dgordon@insulet.com

Source: Insulet Corporation

News Provided by Acquire Media